Skip to content
Evigrade
ModerateVitamin K antagonist anticoagulants×Triazole derivatives, systemic antifungals

Updated · Methodology

Mechanism

In the liver, CYP2C9 is the main enzyme that metabolises acenocoumarol, and CYP1A2 and CYP2C19 also metabolise its more active R-enantiomer (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Voriconazole inhibits CYP2C19, CYP2C9 and CYP3A4 (voriconazole SmPC, European Medicines Agency, EMA). The pair has not been studied, but both voriconazole labels expect levels of other coumarins, acenocoumarol included, to rise and the prothrombin time to lengthen (EMA; voriconazole prescribing information, US Food and Drug Administration, FDA). The only data are for warfarin: voriconazole 300 mg twice daily roughly doubled the maximum prothrombin time after a single 30 mg dose of warfarin (EMA; FDA).

Symptoms

The main risk is bleeding. Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS). Acute kidney injury may occur with excessive anticoagulation and blood in the urine, especially in people with previous kidney disease (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. The voriconazole labels name acenocoumarol among the coumarins that need close monitoring of the prothrombin time or other suitable anticoagulation tests, with anticoagulant dose adjustment (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA; voriconazole prescribing information, US Food and Drug Administration, FDA). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped, including after the end of a voriconazole course (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days (AEMPS). Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (AEMPS). With an international normalised ratio (INR) below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol

Other interactions with Voriconazole